Northern Ireland is set to launch a targeted Meningitis B (MenB) vaccination programme on 31 July 2026, aimed at protecting young people from severe and potentially life-threatening infections. This initiative has been welcomed by health experts, who highlight the importance of vaccinating those most vulnerable to MenB.
The two-dose vaccine will be offered to specific groups, including all Year 14 students and individuals under the age of 25 who are due to start university or higher education for the first time this autumn. This includes those born between 2 July 2007 and 1 July 2008, and those born on or after 21 July 2001 who are starting an undergraduate degree in the UK or Ireland, or living in further education or university halls for the first time (NHS sources). According to NHS England, MenB is a significant concern for young adults due to its highly contagious nature in close-contact environments. Infection can spread through everyday activities like kissing and sharing food/drinks.
The vaccine regimen consists of two doses, ideally administered approximately 28 days apart for maximum effectiveness. To accommodate late arrivals and international students, first doses will be available until 31 December 2026, with second doses offered until 31 March 2027 (NHS England). While details on specific vaccination points are still being finalised, the Chief Medical Officer has indicated a 'mixed delivery model' involving GPs, community pharmacies, and potential on-campus clinics.
A broader MenB vaccination campaign for all teenagers aged 15 and over is also being considered. This move follows a change in advice from the Joint Committee on Vaccination and Immunisation (JCVI), which now recognises teenagers as being more susceptible to contracting and becoming seriously ill from the infection. The Department of Health in Northern Ireland is currently assessing these recommendations, with a policy decision expected in due course.